SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has reported continued expansion of its SSi Mantra surgical robotic system, with substantial increases in both installations and procedure volumes. According to a company update issued September 10, 2026, the installed base of SSi Mantra systems reached 238 as of September 8, 2026, up 42% from 168 at the end of 2025. Cumulative procedures performed using the system climbed to 14,103, representing a 79% increase from 7,885 at year-end 2025.
The company’s global footprint now spans 12 countries, following recent launches in Colombia and Sri Lanka, and further international expansion is underway. This growth underscores the increasing adoption of robotic-assisted surgery worldwide, which can lead to improved patient outcomes, reduced recovery times, and greater access to minimally invasive procedures.
In addition to adult procedures, SS Innovations highlighted the expansion of pediatric applications. Notably, a robotic kidney procedure was performed on a 45-day-old infant in India using 5-millimeter instruments. This milestone demonstrates the system’s versatility and precision in treating even the youngest patients, potentially opening new avenues for pediatric surgical care.
The company also reported 188 cumulative robotic telesurgeries as of August 31, 2026, including long-distance procedures that connect surgeons and patients across countries. Telesurgery can help bridge gaps in surgical expertise, allowing specialist care to reach remote or underserved regions. This capability is particularly relevant as healthcare systems seek to address disparities in access to advanced surgical services.
Looking ahead, SS Innovations expects the U.S. Food and Drug Administration (FDA) to review its 510(k) submission by the end of the first quarter of 2027. Additionally, the company believes it could obtain EU CE marking for the SSi Mantra by the end of 2026. These regulatory milestones, if achieved, would pave the way for entry into two of the world’s largest medical device markets, significantly expanding the company’s addressable market and competitive position.
Approximately 1,500 physicians have now been trained on the SSi Mantra system, according to the update. This growing base of trained surgeons is essential for driving adoption and ensuring safe and effective use of the technology. For investors and industry observers, the expanding procedure volume and installation base signal strong momentum. For patients, the continued global rollout of robotic surgery systems like SSi Mantra may translate into more treatment options and better surgical outcomes. As NEWMEDIAWIRE reported, the company’s progress reflects broader trends in healthcare innovation. More details can be found in the full release available through Read More, and investors can stay updated via the company’s newsroom at https://ibn.fm/SSII.
Forward-looking statements in this article are subject to risks and uncertainties that could cause actual results to differ materially. SS Innovations International undertakes no duty to update such information unless required by law.
